-transparent.png){kind=logo}
MicroRNAs (miRNAs) are differentially expressed in various cancers and act as oncogenes or tumor suppressors. MiR-383 has been characterized as a cancer suppressor in several cancers. However, the exact expression patterns of miR-383 and the precise molecular mechanisms underlying its role in ovarian cancer have not been investigated thoroughly. In this study, we found that the expression of miR-383 was significantly downregulated in ovarian cancer tissues and ovarian cancer cell lines. Ectopic expression of miR-383 remarkably suppressed the ovarian cancer cell proliferation by enhancing cell apoptosis and significantly inhibited the invasion of ovarian cancer cells, while low expression of miR-383 exhibited the opposite effect. Bioinformatics analysis suggested LDHA as a novel target of miR-383, and miR-383 suppressed the expression level of LDHA mRNA by direct binding to its 3'-untranslated region (3'UTR). Expression of miR-383 was negatively correlated with LDHA in ovarian cancer tissues. In addition, modulation of miR-383 expression could affect the aerobic glycolysis in the ovarian cancer cells. Furthermore, Silencing of LDHA counteracted the effects of miR-383 suppression, while its overexpression reversed tumor inhibitory effects of miR-383. In conclusion, our study demonstrated that miR-383 regulated LDHA expression in ovarian cancer cells, thereby stunting glycolysis, cell proliferation and invasion.
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
February 2017,
Iranian journal of basic medical sciences,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
February 2018,
Biochemical and biophysical research communications,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
January 2020,
Oncology reports,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
July 2019,
European review for medical and pharmacological sciences,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
August 2018,
Cellular and molecular biology (Noisy-le-Grand, France),
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
January 2020,
OncoTargets and therapy,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
February 2016,
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
December 2018,
Medical science monitor : international medical journal of experimental and clinical research,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
June 2016,
International journal of experimental pathology,
R L Han, and
F P Wang, and
P A Zhang, and
X Y Zhou, and
Y Li
June 2016,
Oncotarget,
